ImmunoCellular Therapeutics (IMUC) 10-Q 8 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'IMUC	'
Entity Registrant Name	'ImmunoCellular Therapeutics, Ltd.	'
Entity Central Index Key	'0000822411	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	60,665,333

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$25,661,095	$27,646,351
Other assets	966,564	763,299
Total current assets	26,627,659	28,409,650
Property and equipment, net	45,729	66,442
Other assets	464,585	464,585
Total assets	27,137,973	28,940,677
Current liabilities:	'	'
Accounts payable	621,895	861,026
Accrued compensation and benefits	177,731	357,265
Accrued liabilities	322,561	183,982
Total current liabilities	1,122,187	1,402,273
Warrant Liability	1,256,343	1,064,810
Commitments and contingencies (Note 5)	'	'
Shareholders’ equity:	'	'
Common stock, $0.0001 par value; 149,000,000 shares authorized; 60,472,962 and 57,542,231 shares issued and outstanding as of June 30, 2014 and December 31, 2013, respectively	6,047	5,754
Additional paid-in capital	82,083,906	78,437,233
Accumulated deficit	-57,330,510	-51,969,393
Total shareholders’ equity	24,759,443	26,473,594
Total liabilities and shareholders’ equity	$27,137,973	$28,940,677

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	149,000,000	149,000,000
Common stock, shares issued	60,472,962	57,542,231
Common stock, shares outstanding	60,472,962	57,542,231

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues	'	'	'	'
Expenses:	'	'	'	'
Research and development	1,460,044	1,213,570	3,159,804	2,628,831
Stock based compensation	128,548	179,946	312,650	344,074
General and administrative	838,232	788,420	1,703,634	1,557,687
Total expenses	2,426,824	2,181,936	5,176,088	4,530,592
Loss before other income (expense) and income taxes	-2,426,824	-2,181,936	-5,176,088	-4,530,592
Interest income	3,150	4,094	6,504	10,643
Financing expense	-24,600	'	-24,600	'
Change in fair value of warrant liability	249,134	2,027,513	-166,933	-604,171
Loss before income taxes	-2,199,140	-150,329	-5,361,117	-5,124,120
Income taxes	'	'	'	'
Net loss	($2,199,140)	($150,329)	($5,361,117)	($5,124,120)
Net loss per share, basic and diluted:	($0.04)	$0	($0.09)	($0.10)
Weighted average number of shares basic and diluted:	58,535,936	52,972,702	58,047,016	52,264,104

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Shareholders' Equity (Deficit) (USD $)	Total	Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
	USD ($)	USD ($)	Common Stock Issued Through Controlled Equity Offering Average Of 1.21 Per Share	USD ($)	USD ($)
Balance at Dec. 31, 2013	$26,473,594	$5,754	'	$78,437,233	($51,969,393)
Balance, shares at Dec. 31, 2013	'	57,542,231	'	'	'
Cashless exercise of stock options	'	2	'	-2	'
Cashless exercise of stock options, shares	'	23,473	'	'	'
Exercise of stock options	1,045,000	95	'	1,044,905	'
Exercise of stock options, shares	1,025,000	950,000	'	'	'
Common stock issued through controlled equity offering	2,289,316	196	'	2,289,120	'
Common stock issued through controlled equity offering, shares	'	'	1,957,258	'	'
Stock based compensation (options)	312,650	'	'	312,650	'
Stock based compensation (options), shares	'	'	'	'	'
Net loss	-5,361,117	'	'	'	-5,361,117
Balance at Jun. 30, 2014	$24,759,443	$6,047	'	$82,083,906	($57,330,510)
Balance, shares at Jun. 30, 2014	'	60,472,962	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Parenthetical) (Common Stock Issued Through Controlled Equity Offering Average Of 1.21 Per Share, USD $)	6 Months Ended
	Jun. 30, 2014
Common Stock Issued Through Controlled Equity Offering Average Of 1.21 Per Share	'
Common stock issued through controlled equity offering average, per share	$1.21

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($5,361,117)	($5,124,120)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	23,917	21,684
(Gain) loss on disposal of assets	-4	3,817
Change in fair value of warrant liability	166,933	604,171
Financing expense	24,600	'
Stock-based compensation	312,650	344,074
Changes in assets and liabilities:	'	'
Other assets	-203,265	307,594
Accounts payable	-239,131	-403,588
Accrued liabilities	-40,955	128,546
Net cash used in operating activities	-5,316,372	-4,117,822
Cash flows from investing activities:	'	'
Purchase of property and equipment	-3,600	-34,441
Proceeds from sale of property and equipment	400	'
Net cash used in investing activities	-3,200	-34,441
Cash flows from financing activities:	'	'
Proceeds from exercise of stock options	1,045,000	84,131
Proceeds from exercise of warrants	'	3,049,638
Proceeds from issuance of common stock and warrants net of offering costs	2,289,316	404,208
Other assets	'	-150,000
Net cash provided by financing activities	3,334,316	3,387,977
Increase (decrease) in cash and cash equivalents	-1,985,256	-764,286
Cash and cash equivalents, beginning of period	27,646,351	26,216,668
Cash and cash equivalents, end of period	25,661,095	25,452,382
Supplemental cash flows disclosures:	'	'
Interest expense paid	'	'
Income taxes paid	'	'
Supplemental non-cash financing disclosures:	'	'
Warrant liability converted to additional paid-in capital	'	1,145,660
Common stock issued for license rights	'	$75,000

Nature_of_Organization_and_Pla

Nature of Organization and Planned Principal Operations Have Not Commenced	6 Months Ended
	Jun. 30, 2014
Nature of Organization and Planned Principal Operations Have Not Commenced	'
	1. Nature of Organization and Planned Principal Operations Have Not Commenced
	ImmunoCellular Therapeutics, Ltd. (the Company) is a biotechnology company that is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. The Company’s planned principal operations have not commenced as of yet.
	The Company has been primarily engaged in the acquisition of certain intellectual property, together with development of its vaccine product candidates, and has not generated any recurring revenues. The Company’s lead product candidate, ICT-107, is in Phase II clinical development. The Company has two other product candidates, ICT-140 and ICT-121, both with investigational new drug (IND) applications active at the US Food and Drug Administration (FDA). The Company has incurred operating losses and, as of June 30, 2014, the Company had an accumulated deficit of $57,330,510. The Company expects to incur significant research, development and administrative expenses before any of its products can be launched and recurring revenues generated.
	The Company's activities are subject to significant risks and uncertainties, including the failure of any of the Company's product candidates to achieve clinical success or to obtain regulatory approval.  Additionally, it is possible that other companies with competing products and technology might obtain regulatory approval ahead of the Company.  The Company will need significant amounts of additional funding in order to complete the development of any of its product candidates and the availability and terms of such funding cannot be assured.
	Interim Results
	The accompanying condensed consolidated financial statements as of June 30, 2014 and for the three and six month periods ended June 30, 2014 and 2013 are unaudited, but include all adjustments, consisting of normal recurring entries, which the Company’s management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. These financial statements include the Company’s wholly owned subsidiaries, ImmunoCellular Bermuda, Ltd. in Bermuda and ImmunoCellular Therapeutics (Ireland) Limited and ImmunoCellular Therapeutics (Europe) Limited in Ireland, that were formed during the three months ended June 30, 2014.  Balance sheet amounts as of December 31, 2013 have been derived from the Company’s audited financial statements included in its Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission (SEC) on March 14, 2014.
	The consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) have been condensed or omitted pursuant to such rules and regulations. The consolidated financial statements should be read in conjunction with the Company’s audited financial statements in its Form 10-K for the year ended December 31, 2013. The Company’s operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Liquidity – As of June 30, 2014, the Company had working capital of $25,505,472, compared to working capital of $27,007,377 as of December 31, 2013. The estimated cost of completing the development of any of our current vaccine product candidates and of obtaining all required regulatory approvals to market any of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances are sufficient for our currently planned level of operations for at least the next twelve months, although there is no assurance that such proceeds will be sufficient for this purpose.
	Principles of Consolidation - The condensed consolidated balance sheets include the accounts of the Company and its subsidiaries. The consolidated statements of operations include the Company’s accounts and the accounts of its subsidiaries from the date of acquisition. All intercompany transactions and balances have been eliminated in consolidation.
	Cash and cash equivalents – The Company considers all highly liquid instruments with an original maturity of 90 days or less at acquisition to be cash equivalents. As of June 30, 2014 and December 31, 2013, the Company had $22,420,397 and $25,913,893, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments.
	Property and Equipment – Property and equipment are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
	Research and Development Costs – Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred.
	Stock Based Compensation – The Company records the cost for all share-based payment transactions in the Company’s financial statements.
	Stock option grants issued to employees and officers and directors were valued using the Black-Scholes pricing model.
	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Six months			Six months
		Ended			Ended
		30-Jun-14			30-Jun-13
	Risk-free interest rate		2.18	%		0.074	%
	Expected dividend yield		None			None
	Expected life		5.5 Years			4.54 Years
	Expected volatility		95.3	%		90.5	%
	Expected forfeitures		0	%		0	%
	The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the six months ended June 30, 2014 and 2013, the expected volatility is based upon the historical volatility of the Company’s common stock. Forfeitures have been estimated to be nil.
	The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.
	When options are exercised, our policy is to issue reserved but previously unissued shares of common stock to satisfy share option exercises. As of June 30, 2014, the Company had 56,587,180 shares of authorized and unissued common stock.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.
	Income Taxes – The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of June 30, 2014 and December 31, 2013, the Company fully reserved its deferred tax assets. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of June 30, 2014, the Company had no unrecognized tax benefits and as such, no liability, interest or penalties were required to be recorded.  The Company does not expect this to change significantly in the next twelve months.  The Company has determined that its main taxing jurisdictions are the United States of America and the State of California.  The Company is not currently under examination by any taxing authority nor has it been notified of a pending examination. The Company’s tax returns are generally no longer subject to examination for the years before December 31, 2009 for the state and December 31, 2010 for the federal taxing authority.
	Fair Value of Financial Instruments – The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant derivative liability is estimated using the Binomial Lattice option valuation model.
	Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  The Company utilizes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:
	Level 1—quoted prices in active markets for identical assets or liabilities
	Level 2—quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3—inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.
	Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.
	The following critical accounting policies affect the Company’s more significant judgments and estimates used in the preparation of these financial statements:
	Stock-Based Compensation - Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of the company’s stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In connection with performance based programs, the company makes assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met.
	Income Taxes - The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2009 to 2013, remain open for possible review.
	Warrant Liability - The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.  The use of the Binomial Lattice option valuation model requires estimates including the volatility of the company’s stock, risk-free rates over the expected term of warrants and early exercise of the options.
	Basic and Diluted Loss per Common Share – Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation, since the effect would be antidilutive. Common share equivalents which could potentially dilute earnings per share, and which were excluded from the computation of diluted loss per share, totaled 19,710,598 shares and 21,992,841 shares at June 30, 2014 and 2013, respectively.
	Recently Issued Accounting Standards – In June 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-12, which removes the definition of a development stage entity from FASB ASC 915 and eliminates the disclosure requirements for development stage entities to 1) present inception-to-date information on the statements of operations, cash flows and shareholders’ equity; 2) label the financial statements as those of a development stage entity, 3) disclose a description of the development stage activities in which the entity is engaged and 4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been a development stage.  This ASU added a requirement for the entity to disclose its major risks and uncertainties.  The ASU is effective for annual reporting periods beginning after December 15, 2014; however, early adoption is permitted.  The Company decided to adopt this ASU effective in the second quarter of 2014.  The adoption of this ASU did not have a material impact on the Company’s consolidated results of operations, financial condition or liquidity.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2014
Property and Equipment	'
	3. Property and Equipment
	Property and equipment consist of the following:
		30-Jun-14			December 31, 2013
	Computers	$	59,077		$	67,566
	Research equipment		117,809			117,809
			176,886			185,375
	Accumulated depreciation		(131,157	)		(118,933	)
		$	45,729		$	66,442
	Depreciation expense was $11,283 and $10,842  for the three months ended June 30, 2014 and 2013, respectively. Depreciation expense was $23,917 and $21,684 for the six months ended June 30, 2014 and 2013, respectively.

RelatedParty_Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2014
Related-Party Transactions	'
	4. Related-Party Transactions
	Cedars-Sinai Medical Center License Agreement
	Dr. John Yu, our Chief Scientific Officer and former interim Chief Executive Officer, is a neurosurgeon at Cedars-Sinai Medical Center (Cedars-Sinai). In November 2006, the Company entered into a license agreement with Cedars-Sinai under which the Company acquired an exclusive, worldwide license to its technology for use as cellular therapies, including dendritic cell-based vaccines for neurological disorders that include brain tumors and neurodegenerative disorders and other cancers. This technology is covered by a number of issued and pending U.S. and foreign patents and applications, and the term of the license will be until the last to expire of any patent claims that are issued covering this technology.
	As an upfront licensing fee, the Company issued Cedars-Sinai 694,000 shares of its common stock and paid Cedars-Sinai $62,000. Additional specified milestone payments will be required to be paid to Cedars-Sinai when the Company initiates patient enrollment in its first Phase III clinical trial and when it receives FDA marketing approval for its first product.
	The Company has agreed to pay Cedars-Sinai specified percentages of all of its sublicensing income and gross revenues from sales of products based on the licensed technology. To maintain its rights to the licensed technology, the Company must meet certain development and funding milestones. These milestones include, among others, commencing a Phase I clinical trial for a product candidate by March 31, 2007 and raising at least $5,000,000 in funding from equity or other sources by December 31, 2008. The Company satisfied the foregoing funding requirement in 2007 and commenced a Phase I clinical trial in May 2007, which was within the applicable cure period for the milestone requirement. Through December 31, 2009, the Company has paid Cedars-Sinai a total of $166,660 in connection with the Phase I clinical trial. The Company also was required to commence a Phase II clinical trial for a product candidate by December 31, 2008 and a waiver of this requirement was obtained from Cedars-Sinai (see Second Amendment below).
	On June 16, 2008, the Company entered into a First Amendment to Exclusive License Agreement (the Amendment) with Cedars-Sinai. The Amendment amended the License Agreement to include in the Company’s exclusive license from Cedars-Sinai under that agreement an epitope to CD133 and certain related intellectual property. This technology is covered by U.S. patent applications filed by both parties. Pursuant to the Amendment, the Company issued Cedars-Sinai 100,000 shares of the Company’s common stock as an additional license fee for the licensed CD133 epitope technology, which will be subject to the royalty and other terms of the License Agreement.
	On July 22, 2009, the Company entered into a Second Amendment to Exclusive License Agreement (the Second Amendment) with Cedars-Sinai to become effective August 1, 2009. The Second Amendment amended the License Agreement to revise the milestones set forth in the License Agreement that the Company must achieve in order to maintain its license rights under that agreement. The revised milestones include the replacement of a milestone that required commencement of a Phase II clinical trial for the Company’s first product candidate by no later than December 31, 2008 with milestones that require commencement of a Phase I clinical trial for the Company’s second product candidate by no later than June 30, 2010 and commencement of a Phase II clinical trial for one of the Company’s product candidates by no later than March 31, 2012.
	Effective March 23, 2010, the Company entered into a Third Amendment to Exclusive License Agreement (the Third Amendment) with Cedars-Sinai. The Third Amendment amended the License Agreement to revise the milestones set forth in the License Agreement that the Company must achieve in order to maintain its license rights under that agreement. The revised milestones include the replacement of a milestone that required commencement of a Phase I clinical trial for the Company’s second product candidate by no later than June 30, 2010 and commencement of a Phase II clinical trial for one of the Company’s product candidates by no later than March 31, 2012 with a requirement that by September 30, 2011 the Company either commence a Phase II clinical trial for its dendritic cell vaccine candidate or a Phase I clinical trial for its cancer stem cell vaccine candidate. The amendment also added a requirement that the Company obtain certain defined forms of equity or other funding in the amount of at least $2,500,000 by December 31, 2010 and a total of at least $5,000,000 by September 30, 2011. These funding requirements were fully satisfied as of June 30, 2011 and the agreement expired by its terms.
	Effective September 20, 2010, the Company entered into a sponsored research agreement with Cedars-Sinai under which Cedars-Sinai provided services to the Company in developing the ICT-121 vaccine at a total cost of $446,142.  Effective September 20, 2011, the Company entered into Amendment No. 1 extending the agreement to September 19, 2012 at an incremental cost of $294,504.  Effective September 20, 2012, the Company entered into Amendment No. 2 extending the agreement to September 19, 2013 at an incremental cost of $329,832.  This agreement concluded on September 19, 2013 but was extended through March 19, 2014 at an incremental cost of $210,856.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
	5. Commitments and Contingencies
	Sponsored Research Agreements
	In an effort to expand the Company’s intellectual property portfolio to use antigens to create personalized vaccines, the Company has entered into various intellectual property and research agreements. Those agreements are long-term in nature and are discussed below.
	Aptiv Solutions
	The Company has contracted with Aptiv Solutions to provide certain services related to the Company’s ICT-107 Phase II trial. The original agreement was entered into in August of 2010 and provided for estimated payments of approximately $3.3 million for services through September 2013. Subsequently, the Company and Aptiv entered into five contract amendments. Under the first amendment, effective January 20, 2011, Aptiv agreed to provide additional services in conjunction with the Phase II trial of ICT-107 for an additional fee of $469,807. The second amendment, effective February 4, 2012, extended the services to be provided by Aptiv and further increased the fees by $986,783. The second amendment also extended the term of the agreement to March 31, 2014. On January 11, 2013, the third amendment was finalized whereby the services were further extended and the fees were further increased by $608,201. On December 2, 2013, the fourth amendment was finalized whereby additional services were added and the fees were further increased by $319,450.  On June 5, 2014, the fifth amendment was finalized whereby the project schedule was amended and the fees increased by $495,264. The total aggregate fee pursuant to the original agreement and the five modifications is $6.2 million.
	On September 17, 2013, the Company entered into a Master Services Agreement with Aptiv Solutions to provide certain services related to the Company’s products under development.  Simultaneously, the Company and Aptiv entered into Project Agreement Number 1 for the ICT-140 Phase II trial that provides for payments of approximately $2.7 million until completion of the services described therein.  On May 6, 2014, the Company and Aptiv entered into Amendment #1 to Project Agreement Number 1 to amend the project schedule and provide additional services for an additional fee of $170,004.  On July 17, 2014, the Company and Aptiv entered into Project Agreement CD-133 for the ICT-121 Phase I trial that provides for payments of approximately $2.3 million until completion of the services described therein.  See Note 9 – Subsequent Events.
	As of June 30, 2014, the Company’s remaining obligation under the existing commitments is approximately $3.6 million.
	University of Pennsylvania
	On February 13, 2012, the Company entered into a Patent License Agreement with The Trustees of the University of Pennsylvania under which the Company acquired an exclusive, worldwide license relating to patent technology for the production, use and cryopreservation of high-activity dendritic cell cancer vaccines.
	Pursuant to the License Agreement, the Company paid an upfront licensing fee and will be obligated to pay annual license maintenance fees. In addition, the Company has agreed to make payments upon completion of specified milestones and to pay royalties of a specified percentage on net sales, subject to a specified minimum royalty, and sublicensing fees on product sales covered by the license. During the quarter ended June 30, 2014, the Company terminated this Patent License Agreement.
	The Johns Hopkins University Licensing Agreement
	On February 23, 2012, the Company entered into an Exclusive License Agreement, effective as of February 16, 2012, with The Johns Hopkins University (JHU) under which it received an exclusive, worldwide license to JHU’s rights in and to certain intellectual property related to mesothelin-specific cancer immunotherapies.
	Pursuant to the License Agreement, the Company agreed to pay an upfront licensing fee, payable half in cash and half in shares of its common stock, within 30 days of the effective date of the License Agreement and upon issuance of the first U.S. patent covering the subject technology. In addition, the Company has agreed to pay milestone license fees upon completion of specified milestones, customary royalties based on a specified percentage of net sales, sublicensing payments and annual minimum royalties.  Effective September 24, 2013, the Company entered into an Amendment No. 1 to the Exclusive License Agreement that updated certain milestones.
	The University of Pittsburgh Patent License Agreement
	On March 20, 2012, the Company entered into an Exclusive License Agreement with the University of Pittsburgh under which the Company has licensed intellectual property surrounding EphA2, a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies. The License Agreement grants a worldwide exclusive license to the intellectual property for ovarian and pancreatic cancers; and a worldwide non-exclusive license to the intellectual property for brain cancer.
	Pursuant to the License Agreement, the Company agreed to pay an upfront nonrefundable and noncreditable licensing fee and nonrefundable and noncreditable maintenance fees due annually starting 12 months from the anniversary of the effective date of the License Agreement. In addition, the Company has agreed to make certain milestone payments upon completion of specified milestones and to pay customary royalties based on a specified percentage of net sales and sublicensing payments, as applicable.
	Torrey Pines
	On October 1, 2012, the Company entered into a Contract Services Agreement with Torrey Pines under which the Company has engaged Torrey Pines to determine the immunogenicity of certain peptides that are used in conjunction with the Company’s ICT-107 Phase IIb trial and in the development of ICT-140. The Company agreed to pay an upfront nonrefundable and noncreditable fee and is obligated to pay the remainder at the conclusion of the contract. On April 1, 2013, the Company and Torrey Pines expanded the scope of work to be completed by Torrey Pines under an additional Contract Services Agreement. This supplemental agreement provided for the Company to pay an upfront fee and additional fees at the conclusion of the contract. On April 1, 2014, the Company and Torrey Pines entered into an Amended and Restated Contract Services Agreement for Torrey Pines to perform certain additional services in connection with the Company’s vaccine technologies.
	Cedars-Sinai Medical Center
	In connection with the Cedars-Sinai Medical Center License Agreement and sponsored research agreement, the Company has certain commitments as described in Note 4.
	Employment Agreements
	The Company has employment agreements with its management that provide for a base salary, bonus and stock option grants.  The aggregate annual base salary payable to this group is approximately $1.0 million and the potential bonus is approximately $300,000.  Additionally, during the six months ended June 30, 2014, the Company issued an aggregate of 317,500 stock options to its management at a weighted average exercise price of $1.34 that vest over a period of 4 years.
	Operating Lease
	The Company entered into a lease for new office space effective June 15, 2013 and continuing through August 31, 2016 at an initial monthly rental of $8,063. The monthly rental will increase by 3% on each anniversary date of the lease. Rent for the months of August and September 2013 was abated.  Rent expense was approximately $49,000 and $31,000 for the six months ended June 30, 2014 and 2013, respectively.
	Future minimum rentals under the operating lease are as follows:
	Years ending December 31,	Amount
	2014	$	49,346
	2015		100,905
	2016		68,432
	Total	$	218,683

Shareholders_Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2014
Shareholders Equity	'
	6. Shareholders’ Equity
	Controlled Equity Offering
	On April 18, 2013, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the Sales Agreement) with Cantor Fitzgerald & Co., as agent (Cantor), pursuant to which the Company may offer from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $25.0 million (of which only $17.0 million is currently registered for offer and sale). Under the Sales Agreement, Cantor may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act, as amended, including sales made directly on the NYSE MKT, on any other existing trading market for our common stock or to or through a market maker. The Company may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by us from time to time. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. Cantor will receive a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and the Company has agreed to provide Cantor with customary indemnification and contribution rights. The Company will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement.  On April 22, 2013, NYSE MKT approved the listing of 10,593,220 shares of our common stock in connection with the Sales Agreement. Through June 30, 2014, we sold 3,819,400 shares of our common stock under the Sales Agreement that resulted in proceeds to the Company of approximately $7,049,113, less offering expenses of approximately $354,000.  During the six months ended June 30, 2014, the Company sold 1,957,258 shares of its common stock that resulted in net proceeds to the Company of $2,289,316.  As of June 30, 2014, aggregate gross sales for additional common stock of approximately $9,377,457 remained available under the Sales Agreement.  Subsequent to June 30, 2014, the Company sold 187,371 shares of its common stock that resulted in net proceeds to the Company of $202,425. (See Note 9 – Subsequent Events)
	Stock Options
	In February 2005, the Company adopted an Equity Incentive Plan (the Plan). Pursuant to the Plan, a committee appointed by the Board of Directors may grant, at its discretion, qualified or nonqualified stock options, stock appreciation rights and may grant or sell restricted stock to key individuals, including employees, nonemployee directors, consultants and advisors. Option prices for qualified incentive stock options (which may only be granted to employees) issued under the plan may not be less than 100% of the fair market value of the common stock on the date the option is granted (unless the option is granted to a person who, at the time of grant, owns more than 10% of the total combined voting power of all classes of stock of the Company; in which case the option price may not be less than 110% of the fair market value of the common stock on the date the option is granted). Option prices for nonqualified stock options issued under the Plan are at the discretion of the committee and may be equal to, greater or less than fair market value of the common stock on the date the option is granted. The options vest over periods determined by the Board of Directors and are exercisable no later than ten years from date of grant (unless they are qualified incentive stock options granted to a person owning more than 10% of the total combined voting power of all classes of stock of the Company, in which case the options are exercisable no later than five years from date of grant). Initially, the Company reserved 6,000,000 shares of common stock for issuance under the Plan. On October 24, 2011, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 8,000,000 shares. On September 20, 2013, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 12,000,000 shares. Options to purchase 3,647,158 common shares have been granted under the Plan and are outstanding as of June 30, 2014. As of June 30, 2014, there were 5,424,914 options available for issuance under the Plan.
	During the six months ended June 30, 2014, the Company issued 204,617 stock options to members of the Company’s Board of Directors at an exercise price of $1.19 and a vesting period of 4 years.
	The following table summarizes stock option activity for the Company during the six months ended June 30, 2014:
		Options		Weighted				Weighted		Aggregate
				Average				Average		Intrinsic
				Exercise				Remaining		Value
				Price				Contractual
								Term
	Outstanding December 31, 2013	10,466,695		$	1.37				0		0
	Granted	547,117		$	1.28				0		0
	Exercised	(1,025,000	)	$	1.09				0		0
	Forfeited or expired	(258,230	)	$	2.79				0		0
	Outstanding June 30, 2014	9,730,582		$	1.33				3.45	$	856,067
	Vested or expected to vest at June 30, 2014	7,912,307		$	1.17				2.73	$	856,067
	As of June 30, 2014, the total unrecognized compensation cost related to unvested stock options amounted to $3.3 million, which will be recognized over the weighted-average remaining requisite service period of approximately 19 months.
	Warrants
	In connection with the May 2010 common stock private placement, the Company issued to the investors warrants to purchase 1,287,773 shares of the Company’s common stock at $1.50 per share. The warrants had a term of 36 months from the date of issuance. As of June 30, 2014 these warrants have been fully exercised, except for warrants to purchase 4,000 shares of the Company’s common stock that expired. (See “Warrant Liability” below.)
	In connection with the sale of Preferred Stock in May 2010, the Company issued warrants to purchase 1,350,000 shares of common stock at an exercise price of $2.50. The warrants have a five-year term from the date of issuance. As of June 30, 2014, warrants to purchase 1,290,996 shares of the Company’s common stock at $2.50 remain outstanding related to this private placement. (See “Warrant Liability” below.)
	In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,609,898 shares of the Company’s common stock at $2.25 per share. The warrants have a five-year term from the date of issuance and contain a provision that provides for an adjustment to the exercise price in the event the Company completes an equity financing at a per share price of its common stock that is less than the adjusted exercise price. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,670 net of exercises. During the six months ended June 30, 2014, the exercise price was further adjusted to $1.85 and the number of warrants outstanding was increased to 2,854,196 to reflect the issuances pursuant to the Company’s Controlled Equity OfferingSM.  As of June 30, 2014, warrants to purchase 2,854,196 shares of the Company’s common stock remain outstanding related to this private placement. (See “Warrant Liability” below.)
	In connection with the January 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,744,718 shares of the Company’s common stock at $1.41 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of June 30, 2014, warrants to purchase 1,418,575 shares of the Company’s common stock remain outstanding relating to this public offering.
	In connection with the October 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,500,000 shares of the Company’s common stock at $2.65 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of June 30, 2014, warrants to purchase 4,446,775 shares of the Company’s common stock remain outstanding relating to this public offering.
	Warrant Liability
	The Company’s warrant liability is adjusted to fair value each reporting period and is influenced by several factors including the price of the Company’s common stock as of the balance sheet date. On June 30, 2014, the price per share of Company’s common stock was $1.12 per share compared to $0.93 per share at December 31, 2013.
	In connection with the May 2010 common stock private placement, the Company issued to the investors warrants to purchase 1,287,773 shares of the Company’s common stock at $1.50 per share. Of the total proceeds from the May 2010 common stock private placement, $834,455 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that future common stock issuances are made at a price less than $1.00. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. Prior to 2011, the Company had concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the binomial lattice simulation model, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 1.375%, and (iv) contractual life of 36 months. Effective January 1, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. For the three months ended June 30, 2013, the Company recorded a credit to other income of $403,665 and for the six months ended June 30, 2013, the Company recognized a charge to other expense of $583,134. During 2013, the remaining warrants were fully exercised.
	In connection with the sale of Preferred Stock in 2010, the Company issued to the investors warrants to purchase 1,350,000 shares of the Company’s common stock at an exercise price of $2.50 per share. Of the total proceeds from the May 2010 preferred stock sale, $5,710,500 was allocated to the freestanding warrants associated with the units based upon the fair value of these warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant may be settled for cash in connection with a change of control with a private company. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period and any change in value is recognized in the statement of operations. Prior to 2011, the Company concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the Monte Carlo or binomial lattice simulation models, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 2.50%, and (iv) contractual life of 60 months. Effective January 1, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. For the three and six months ended June 30, 2013, the Company recorded a credit to other income of $480,250 and $2,582,respectively. As of June 30, 2014, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 141%; (iii) risk free rate of 0.10% and (iv) expected term of 0.84 years. For the three months ended June 30, 2014, the Company recorded a credit to other income of $73,587 and for the six months ended June 30, 2014, the Company recorded a charge to other expense of $51,640.  As of June 30, 2014, the carrying value of the warrant liability is $320,167.
	In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,818,675 shares of the Company’s common stock at $2.25 per share. Of the total proceeds from the February 2011 common stock private placement, $2,476,790 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Binomial lattice model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $1.55. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,670 net of exercises. The Company recorded a charge to financing expense of $368,524 to reflect the issuance of the additional warrants. As of result of the Company’s Controlled Equity Offering through June 30, 2014, the exercise price of the warrants was adjusted to $1.85 and the number of warrants was proportionately increased to 2,854,196, net of exercises. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. The Company initially valued these warrants using a binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 146%; (iii) risk free rate of 1.96% and (iv) expected term of 5 years. Based upon those calculations, the Company calculated the initial valuation of the warrants to be $2,476,790. For the three months ended June 30, 2013, the Company recorded a credit to other income of $1,143,597 and for the six months ended June 30, 2013, the Company recorded a charge to other expense of $23,619.  As of June 30, 2014, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 109%; (iii) risk free rate of 0.34% and (iv) expected term of 1.64 years. For the three months ended June 30, 2014, the Company recorded a credit to other income of $175,547 and for the six months ended June 30, 2014, the Company recorded a charge to other expense of $115,293. As of June 30, 2014, the carrying value of the warrant liability is $936,176.
	For the six months ended June 30, 2014 and 2013, the expected volatility is based upon the historical volatility of the Company’s stock.
	The following reconciliation of the beginning and ending balances for all warrant liabilities measured at fair market value on a recurring basis using significant unobservable inputs (level 3) during the period ended June 30, 2014 and 2013:
		30-Jun-14			30-Jun-13
	Balance – January 1	$	1,064,810		$	2,852,880
	Issuance of warrants and effect of repricing		24,600			0
	Exercise of warrants		0			(1,145,660	)
	(Gain) or loss included in earnings		166,933			604,171
	Transfers in and out/or out of Level 3		0			0
	Balance – June 30	$	1,256,343		$	2,311,391

401K_Profit_Sharing_Plan

401(K) Profit Sharing Plan	6 Months Ended
	Jun. 30, 2014
401(k) Profit Sharing Plan	'
	7. 401(k) Profit Sharing Plan
	During 2011, the Company adopted a Profit Sharing Plan that qualifies under Section 401(k) of the Internal Revenue Code. Contributions to the plan are at the Company’s discretion. The Company did not make any matching contributions during the three and six months ended June 30, 2014 or June 30, 2013.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes	'
	8. Income Taxes
	Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards and stock-based compensation.
	As of June 30, 2014, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with its deferred tax assets. Accordingly, a valuation allowance has been established for the full amount of the deferred tax assets.
	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:
		30-Jun-14			30-Jun-13
	Income tax benefit at the federal statutory rate		-34	%		-34	%
	State income tax benefit, net of federal tax benefit		-6	%		-6	%
	Change in fair value of warrant liability		-1	%		5	%
	Change in valuation allowance for deferred tax assets		41	%		35	%
	Total		0	%		0	%
		30-Jun-14			December 31, 2013
	Net operating loss carryforwards	$	17,935,529		$	15,759,274
	Stock-based compensation		2,146,047			2,020,987
	Less valuation allowance		(20,081,576	)		(17,780,261	)
	Net deferred tax asset	$	0		$	0
	As of June 30, 2014 and December 31, 2013, the Company had federal and California income tax net operating loss carry forwards of approximately $46.0 million and $41.0 million respectively. These net operating losses will begin to expire in 2022 and 2016, respectively, unless previously utilized.
	Section 382 of the Internal Revenue Code can limit the amount of net operating losses which may be utilized if certain changes to a company’s ownership occur. While the Company underwent an ownership change in 2012 as defined by Section 382 of the Internal Revenue Code, management estimated that the Company had not incurred any limitations on its ability to utilize its net operating losses under Section 382 of the Internal Revenue Code during 2012. The Company may incur limitations in the future if there is a change in ownership as computed under the prescribed method of the Internal Revenue Code.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events	'
	9. Subsequent Events
	Subsequent to June 30, 2014, the Company sold 187,371 shares of its common stock under the controlled equity offering, which resulted in net proceeds of approximately $202,425 (See Note 6).  Aggregate gross sales for additional common stock of approximately $9,168,770 remain available under the Sales Agreement.
	On July 17, 2014, the Company and Aptiv Solutions entered into Project Agreement CD-133 for the ICT-121 Phase I trial that provides for payments of approximately $2.3 million until completion of the services described therein.
	Subsequent to June 30, 2014, the Company issued 5,000 shares of common stock upon the cashless exercise of options to purchase 50,000 shares of common stock.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Liquidity	'
	Liquidity – As of June 30, 2014, the Company had working capital of $25,505,472, compared to working capital of $27,007,377 as of December 31, 2013. The estimated cost of completing the development of any of our current vaccine product candidates and of obtaining all required regulatory approvals to market any of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances are sufficient for our currently planned level of operations for at least the next twelve months, although there is no assurance that such proceeds will be sufficient for this purpose.
Principles of Consolidation	'
	Principles of Consolidation - The condensed consolidated balance sheets include the accounts of the Company and its subsidiaries. The consolidated statements of operations include the Company’s accounts and the accounts of its subsidiaries from the date of acquisition. All intercompany transactions and balances have been eliminated in consolidation.
Cash and cash equivalents	'
	Cash and cash equivalents – The Company considers all highly liquid instruments with an original maturity of 90 days or less at acquisition to be cash equivalents. As of June 30, 2014 and December 31, 2013, the Company had $22,420,397 and $25,913,893, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments.
Property and Equipment	'
	Property and Equipment – Property and equipment are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
Research and Development Costs	'
	Research and Development Costs – Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred.
Stock Based Compensation	'
	Stock Based Compensation – The Company records the cost for all share-based payment transactions in the Company’s financial statements.
	Stock option grants issued to employees and officers and directors were valued using the Black-Scholes pricing model.
	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Six months			Six months
		Ended			Ended
		30-Jun-14			30-Jun-13
	Risk-free interest rate		2.18	%		0.074	%
	Expected dividend yield		None			None
	Expected life		5.5 Years			4.54 Years
	Expected volatility		95.3	%		90.5	%
	Expected forfeitures		0	%		0	%
	The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the six months ended June 30, 2014 and 2013, the expected volatility is based upon the historical volatility of the Company’s common stock. Forfeitures have been estimated to be nil.
	The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.
	When options are exercised, our policy is to issue reserved but previously unissued shares of common stock to satisfy share option exercises. As of June 30, 2014, the Company had 56,587,180 shares of authorized and unissued common stock.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.
Income Taxes	'
	Income Taxes – The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of June 30, 2014 and December 31, 2013, the Company fully reserved its deferred tax assets. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of June 30, 2014, the Company had no unrecognized tax benefits and as such, no liability, interest or penalties were required to be recorded.  The Company does not expect this to change significantly in the next twelve months.  The Company has determined that its main taxing jurisdictions are the United States of America and the State of California.  The Company is not currently under examination by any taxing authority nor has it been notified of a pending examination. The Company’s tax returns are generally no longer subject to examination for the years before December 31, 2009 for the state and December 31, 2010 for the federal taxing authority.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments – The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant derivative liability is estimated using the Binomial Lattice option valuation model.
	Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  The Company utilizes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:
	Level 1—quoted prices in active markets for identical assets or liabilities
	Level 2—quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3—inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.
Use of Estimates	'
	Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.
Basic and Diluted Loss per Common Share	'
	Basic and Diluted Loss per Common Share – Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation, since the effect would be antidilutive. Common share equivalents which could potentially dilute earnings per share, and which were excluded from the computation of diluted loss per share, totaled 19,710,598 shares and 21,992,841 shares at June 30, 2014 and 2013, respectively.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards – In June 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-12, which removes the definition of a development stage entity from FASB ASC 915 and eliminates the disclosure requirements for development stage entities to 1) present inception-to-date information on the statements of operations, cash flows and shareholders’ equity; 2) label the financial statements as those of a development stage entity, 3) disclose a description of the development stage activities in which the entity is engaged and 4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been a development stage.  This ASU added a requirement for the entity to disclose its major risks and uncertainties.  The ASU is effective for annual reporting periods beginning after December 15, 2014; however, early adoption is permitted.  The Company decided to adopt this ASU effective in the second quarter of 2014.  The adoption of this ASU did not have a material impact on the Company’s consolidated results of operations, financial condition or liquidity.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.
Critical Accounting Policies	'
Stock Based Compensation	'
	Stock-Based Compensation - Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of the company’s stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In connection with performance based programs, the company makes assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met.
Income Taxes	'
	Income Taxes - The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2009 to 2013, remain open for possible review.
Warrant Liability	'
	Warrant Liability - The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.  The use of the Binomial Lattice option valuation model requires estimates including the volatility of the company’s stock, risk-free rates over the expected term of warrants and early exercise of the options.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Schedule of Stock Options Grants	'
	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Six months			Six months
		Ended			Ended
		30-Jun-14			30-Jun-13
	Risk-free interest rate		2.18	%		0.074	%
	Expected dividend yield		None			None
	Expected life		5.5 Years			4.54 Years
	Expected volatility		95.3	%		90.5	%
	Expected forfeitures		0	%		0	%

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Components of Property and Equipment	'
	Property and equipment consist of the following:
		30-Jun-14			December 31, 2013
	Computers	$	59,077		$	67,566
	Research equipment		117,809			117,809
			176,886			185,375
	Accumulated depreciation		(131,157	)		(118,933	)
		$	45,729		$	66,442

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2014
Future Minimum Rentals Under Operating Lease	'
	Future minimum rentals under the operating lease are as follows:
	Years ending December 31,	Amount
	2014	$	49,346
	2015		100,905
	2016		68,432
	Total	$	218,683

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Stock Options Activity	'
	The following table summarizes stock option activity for the Company during the six months ended June 30, 2014:
		Options		Weighted				Weighted		Aggregate
				Average				Average		Intrinsic
				Exercise				Remaining		Value
				Price				Contractual
								Term
	Outstanding December 31, 2013	10,466,695		$	1.37				0		0
	Granted	547,117		$	1.28				0		0
	Exercised	(1,025,000	)	$	1.09				0		0
	Forfeited or expired	(258,230	)	$	2.79				0		0
	Outstanding June 30, 2014	9,730,582		$	1.33				3.45	$	856,067
	Vested or expected to vest at June 30, 2014	7,912,307		$	1.17				2.73	$	856,067
Summary of Carrying Value of Warrant Liability	'
	The following reconciliation of the beginning and ending balances for all warrant liabilities measured at fair market value on a recurring basis using significant unobservable inputs (level 3) during the period ended June 30, 2014 and 2013:
		30-Jun-14			30-Jun-13
	Balance – January 1	$	1,064,810		$	2,852,880
	Issuance of warrants and effect of repricing		24,600			0
	Exercise of warrants		0			(1,145,660	)
	(Gain) or loss included in earnings		166,933			604,171
	Transfers in and out/or out of Level 3		0			0
	Balance – June 30	$	1,256,343		$	2,311,391

Income_Taxes_Tables

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2014
Federal Statutory Income Tax Rate to Loss before Income Taxes	'
	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:
		30-Jun-14			30-Jun-13
	Income tax benefit at the federal statutory rate		-34	%		-34	%
	State income tax benefit, net of federal tax benefit		-6	%		-6	%
	Change in fair value of warrant liability		-1	%		5	%
	Change in valuation allowance for deferred tax assets		41	%		35	%
	Total		0	%		0	%
Deferred Tax Asset	'
		30-Jun-14			December 31, 2013
	Net operating loss carryforwards	$	17,935,529		$	15,759,274
	Stock-based compensation		2,146,047			2,020,987
	Less valuation allowance		(20,081,576	)		(17,780,261	)
	Net deferred tax asset	$	0		$	0

Nature_of_Organization_and_Pla1

Nature of Organization and Planned Principal Operations Have Not Commenced (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Nature of Organization (Textual) [Abstract]	'	'
Deficit accumulated during the development stage	$57,330,510	$51,969,393

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Summary Of Significant Accounting Policies (Additional Textual) [Abstract]	'	'	'
Working capital	$25,505,472	'	$27,007,377
Original maturity of highly liquid instruments	'90 days	'	'
Certificates of deposit	22,420,397	'	25,913,893
Estimated useful lives of property and equipment	'generally three to five years	'	'
Expected forfeitures	0.00%	0.00%	'
Shares authorized but unissued common stock	56,587,180	'	'
Tax benefit attributed to the stock-based compensation expense	0	'	'
Unrecognized tax benefits	0	'	'
Unrecognized tax benefits, income tax penalties and interest accrued	$0	'	'
Shares excluded from the computation of diluted net loss per share	19,710,598	21,992,841	'
Computer Equipment	'	'	'
Summary of Significant Accounting Policies (Textual) [Abstract]	'	'	'
Computer and computer equipment depreciation period	'3 years	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Schedule of stock options grants	'	'
Risk-free interest rate	2.18%	0.07%
Expected dividend yield	0.00%	0.00%
Expected life	'5 years 6 months	'4 years 6 months 15 days
Expected volatility	95.30%	90.50%
Expected forfeitures	0.00%	0.00%

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Components of Property and Equipment	'	'
Property and equipment, gross	$176,886	$185,375
Accumulated depreciation	-131,157	-118,933
Property and equipment, net	45,729	66,442
Computer Equipment	'	'
Components of Property and Equipment	'	'
Property and equipment, gross	59,077	67,566
Research Equipment	'	'
Components of Property and Equipment	'	'
Property and equipment, gross	$117,809	$117,809

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property and Equipment (Textual) [Abstract]	'	'	'	'
Depreciation expense	$11,283	$10,842	$23,917	$21,684

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	1 Months Ended	12 Months Ended		32 Months Ended					12 Months Ended
	Nov. 30, 2006	Sep. 19, 2013	Sep. 20, 2010	Dec. 31, 2009	Sep. 30, 2011	Dec. 31, 2010	Dec. 31, 2008	Jun. 16, 2008	Sep. 20, 2011	Sep. 20, 2012
									Amendment No. 1	Amendment No. 2
Related Party Transactions (Textual) [Abstract]	'	'	'	'	'	'	'	'	'	'
Common stock, shares issued	694,000	'	'	'	'	'	'	'	'	'
Payment for upfront licensing fee	$62,000	'	'	'	'	'	'	'	'	'
Funding from equity	'	'	'	'	'	'	5,000,000	'	'	'
Payment to related Party	'	'	'	166,660	'	'	'	'	'	'
Shares issued to related parties	'	'	'	'	'	'	'	100,000	'	'
Other funding to related parties	'	'	'	'	5,000,000	2,500,000	'	'	'	'
Expected final contract price	'	$210,856	$446,142	'	'	'	'	'	$294,504	$329,832

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Details) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 05, 2014

6-May-14

Dec. 02, 2013

Jan. 11, 2013

Feb. 29, 2012

Jan. 20, 2011

Jun. 30, 2014

Sep. 17, 2013

Jul. 17, 2014

Jun. 30, 2014

Aptiv Solution

Aptiv Solution

Aptiv Solution

Aptiv Solution

Aptiv Solution

Aptiv Solution

Aptiv Solution

Aptiv Solution

Aptiv Solution

Employment Agreement With Management

ContractAmendments

Subsequent Event

Commitments And Contingencies Textual [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for services

'

'

'

'

'

'

'

'

'

'

$3,300,000

'

'

'

Number of contract amendments

'

'

'

'

'

'

'

'

'

'

5

'

'

'

Amendment additional fee

'

'

'

'

495,264

170,004

319,450

608,201

986,783

469,807

'

'

'

'

Extended agreement date

'

'

31-Mar-14

'

'

'

'

'

'

'

'

'

'

'

Total aggregate fee

'

'

'

'

'

'

'

'

'

'

6,200,000

'

'

'

Estimated payments for services

'

'

'

'

'

'

'

'

'

'

'

2,700,000

2,300,000

'

Company's remaining commitment obligation

'

'

'

'

'

'

'

'

'

'

3,600,000

'

'

'

Period within effective date of License Agreement

'

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

Nonrefundable And Noncreditable License And Maintenance Fee

'

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

Base salary

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

Discretionary cash bonus

0

0

0

0

'

'

'

'

'

'

'

'

'

300,000

Purchase of stock option

'

'

547,117

'

'

'

'

'

'

'

'

'

'

317,500

Exercise option price

'

'

$1.28

'

'

'

'

'

'

'

'

'

'

$1.34

Incentive stock option grant, period

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

Lease monthly rent

8,063

'

8,063

'

'

'

'

'

'

'

'

'

'

'

Operating lease rent expense

'

'

$49,000

$31,000

'

'

'

'

'

'

'

'

'

'

Percentage of annual increase of monthly base rent

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies (Details) (USD $)	Jun. 30, 2014
Future Minimum Rentals Under the Operating Lease	'
2014	$49,346
2015	100,905
2016	68,432
Operating lease obligation total	$218,683

Shareholders_Equity_Details_Te

Shareholders' Equity (Details Textual) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

12 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

14 Months Ended

Apr. 22, 2013

Apr. 18, 2013

Oct. 31, 2012

Jan. 31, 2012

Feb. 28, 2011

31-May-10

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Oct. 24, 2011

Feb. 28, 2005

Jun. 30, 2014

31-May-10

31-May-10

Mar. 31, 2010

Jun. 30, 2013

Jun. 30, 2013

31-May-10

Feb. 28, 2011

Jun. 30, 2014

Feb. 28, 2011

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Feb. 28, 2011

Dec. 31, 2011

Jun. 30, 2014

Feb. 28, 2011

Jun. 30, 2014

Oct. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

31-May-10

Feb. 28, 2011

31-May-10

Jun. 30, 2014

Mar. 31, 2010

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Apr. 18, 2013

Apr. 18, 2013

Binomial Simulation

Warranty Obligations

May

May

May

May

May

February

February

February

February

February

February

February

February

February

February

January

October

October

Warrant

Warrant

Warrant

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Members of Board of Directors

Stock Compensation Plan

Cantor Fitzgerald & Co.

Cantor Fitzgerald & Co.

Cantor Fitzgerald & Co.

Cantor Fitzgerald & Co.

Warranty Obligations

Maximum

Binomial Simulation

Binomial Simulation

Binomial Simulation

Binomial Simulation

Binomial Simulation

Binomial Lattice Simulation

Warranty Obligations

May

February

May

May

May

May

May

May

Offer and sale

Previous Valuation Assumptions

Previous Valuation Assumptions

Binomial Simulation

Binomial Lattice Simulation

Binomial Lattice Simulation

Binomial Lattice Simulation

Shareholders' Equity Textual [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock aggregate offering price

'

'

'

'

'

'

$6,047

$6,047

$5,754

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000,000

$17,000,000

Commission rate

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Listing of shares of common stock in connection with Sales Agreement

10,593,220

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash, shares

'

'

'

'

'

'

'

187,371

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,957,258

3,819,400

'

'

Proceeds from Issuance of common stock

'

'

'

'

'

'

'

202,425

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,289,316

7,049,113

'

'

Additional common stock sales gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,377,457

9,377,457

'

'

Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs

'

'

'

'

'

'

'

354,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of fair market value of common stock

'

'

'

'

'

'

'

'not be less than 100%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of common stock voting rights held

'

'

'

'

'

'

'

'more than 10%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum percentage of fair market value of common stock

'

'

'

'

'

'

'

'less than 110%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum exercisable period of options

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum exercisable period of options if percentage of common stock voting rights held is more than ten percent

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized under the plan

'

'

'

'

'

'

12,000,000

12,000,000

'

8,000,000

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares granted and outstanding

'

'

'

'

'

'

9,730,582

9,730,582

10,466,695

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,647,158

'

'

'

'

Stock options available for issuance

'

'

'

'

'

'

5,424,914

5,424,914

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to unvested stock options

'

'

'

'

'

'

3,300,000

3,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average remaining requisite service period

'

'

'

'

'

'

'

'19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of common stock, shares

'

'

'

4,744,718

'

'

'

'

'

'

'

'

'

'

'

'

'

1,287,773

'

'

'

'

'

'

'

'

'

2,818,675

'

4,500,000

'

'

1,287,773

2,609,898

1,350,000

'

'

'

'

'

'

'

'

'

'

'

Common stock, price per share

'

'

'

$1.41

'

'

'

$1.12

$0.93

'

'

'

'

'

'

'

'

$1.50

'

'

'

'

'

'

'

'

'

$2.25

'

'

'

'

$1.50

$2.25

$2.50

$2.50

'

'

'

'

'

'

'

'

'

'

Warrant Exercise Term Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'36 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Warrants Expired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Shares Purchased Private Placement Warrant

'

'

2,823,670

'

'

'

2,854,196

2,854,196

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,418,575

'

4,446,775

'

'

'

'

1,290,996

'

'

'

'

'

'

'

'

'

'

Warrants exercisable period after initial issuance

'

'

'

'5 years

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants outstanding increased net of exercises

'

'

2,823,670

'

'

'

'

2,854,196

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjusted exercise price of warrants

'

'

$1.87

$1.87

'

'

'

$1.85

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.65

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from the common stock private placement

'

'

'

'

'

834,455

'

'

'

'

'

'

'

'

'

'

'

'

2,476,790

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future common stock issuance price

'

'

'

'

'

'

'

'

'

'

'

'

'less than $1.00

'

'

'

'

'

'

'

'less than $1.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend yield rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

0.00%

'

0.00%

'

'

'

'

'

'

'

Expected volatility rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

102.00%

'

'

'

'

'

'

'

'

'

'

146.00%

109.00%

'

'

'

'

'

'

'

'

'

102.00%

'

141.00%

'

'

'

'

'

'

'

Risk-free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.38%

'

'

'

'

'

'

'

'

'

'

1.96%

0.34%

'

'

'

'

'

'

'

'

'

2.50%

'

0.10%

'

'

'

'

'

'

'

Contractual life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'36 months

'

'

'

'

'

'

'

'

'

'

'5 years

'1 year 7 months 21 days

'

'

'

'

'

'

'

'

'

'60 months

'

'10 months 2 days

'

'

'

'

'

'

'

Change in fair value of warrant liability credited to other income

'

'

'

'

'

'

73,587

'

'

'

'

175,547

'

'

'

403,665

'

'

'

'

'

1,143,597

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charge to other expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

583,134

'

'

'

'

'

115,293

23,619

'

'

'

'

'

'

'

'

'

'

'

'

'

480,250

51,640

2,582

'

'

'

'

'

'

Proceeds from warrant shares attributed to free standing warrants related party of investor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,710,500

'

'

'

'

'

'

'

'

'

'

'

Warrant liability carrying value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

936,176

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

320,167

'

'

'

'

'

'

'

'

'

'

Charge to financing expense

'

'

'

'

'

'

'

368,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial valuation of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,476,790

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of stock option

'

'

'

'

'

'

'

547,117

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

204,617

'

'

'

'

'

Exercise option price

'

'

'

'

'

'

'

$1.28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.19

'

'

'

'

'

Vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Summary of stock option activity	'
Options outstanding, Beginning Balance	10,466,695
Purchase of stock option	547,117
Options, Exercised	-1,025,000
Options, Forfeited or expired	-258,230
Options outstanding, Ending Balance	9,730,582
Options, Vested or expected to vest	7,912,307
Weighted Average Exercise Price, Outstanding, Beginning Balance	$1.37
Exercise option price	$1.28
Weighted Average Exercise Price, Exercised	$1.09
Weighted Average Exercise Price, Forfeited or expired	$2.79
Weighted Average Exercise Price, Outstanding, Ending Balance	$1.33
Weighted Average Exercise Price, Vested or expected to vest	$1.17
Weighted Average Contractual Term, Outstanding	'3 years 5 months 12 days
Weighted Average Contractual Term, Vested or expected to vest	'2 years 8 months 23 days
Aggregate Intrinsic Value, Outstanding	$856,067
Aggregate Intrinsic Value, Vested or expected to vest	$856,067

Shareholders_Equity_Details_1

Shareholders' Equity (Details 1) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Summary of carrying value of warrant liability	'	'
Beginning Balance, January 1	$1,064,810	$2,852,880
Issuance of warrants and effect of repricing	24,600	0
Exercise of warrants	0	-1,145,660
(Gain) or loss included in earnings	166,933	604,171
Transfers in and out/or out of Level 3	0	0
Ending Balance, June 30	$1,256,343	$2,311,391

401k_Profit_Sharing_Plan_Detai

401(k) Profit Sharing Plan (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
401(k) Profit Sharing Plan (Textual) [Abstract]	'	'	'	'
Discretionary cash bonus	$0	$0	$0	$0

Income_Taxes_Details

Income Taxes (Details)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Federal statutory income tax rate to loss before income taxes	'	'
Income tax benefit at the federal statutory rate	-34.00%	-34.00%
State income tax benefit, net of federal tax benefit	-6.00%	-6.00%
Change in fair value of warrant liability	-1.00%	5.00%
Change in valuation allowance for deferred tax assets	41.00%	35.00%
Total	0.00%	0.00%

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Deferred Tax Asset	'	'
Net operating loss carryforwards	$17,935,529	$15,759,274
Stock-based compensation	2,146,047	2,020,987
Less valuation allowance	-20,081,576	-17,780,261
Net deferred tax asset	$0	$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013
		Federal	Federal	California	California
Income Taxes (Additional Textual) [Abstract]	'	'	'	'	'
Net operating losses expiration date	'expire in 2022 and 2016	'	'	'	'
Income tax net operating loss carryforwards	'	$46	$41	$46	$41

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	6 Months Ended		6 Months Ended		6 Months Ended
	Jun. 30, 2014	Sep. 17, 2013	Jun. 30, 2014	Jul. 17, 2014	Jun. 30, 2014
		Aptiv Solution	Subsequent Event	Subsequent Event	Subsequent Event
				Aptiv Solution	Controlled Equity Offering
Subsequent Event [Line Items]	'	'	'	'	'
Common stock issued for cash, shares	187,371	'	5,000	'	187,371
Proceeds from Issuance of common stock	$202,425	'	$202,425	'	'
Aggregate gross sales for additional common stock to be issued	'	'	9,168,770	'	'
Estimated payments for services	'	$2,700,000	'	$2,300,000	'
Number of common stock to be purchased upon cashless exercise of options	'	'	50,000	'	'